GMAB – Genmab A/S

Genmab A/S

GMAB

$20.04

Name : Genmab A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $12,541,773,824.00

EPSttm : 1.84

Genmab A/S

$20.04

2.51%

$0.49

Float Short %

0.35

Margin Of Safety %

Put/Call OI Ratio

0.61

EPS Next Q Diff

-0.18

EPS Last/This Y

-0.39

EPS This/Next Y

0.31

Price

20.04

Target Price

30.93

Analyst Recom

1.85

Performance Q

-5.56

Relative Volume

0.7

Beta

1.01

Ticker: GMAB

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-20	GMAB	19.85	0.57	6.14	17804
2025-03-21	GMAB	19.77	0.57	5.50	17765
2025-03-24	GMAB	19.31	0.55	0.45	16515
2025-03-25	GMAB	19.06	0.55	0.07	16578
2025-03-26	GMAB	19.64	0.55	0.02	16596
2025-03-27	GMAB	20.15	0.55	1.33	16638
2025-03-28	GMAB	19.91	0.55	7.25	16639
2025-03-31	GMAB	19.58	0.55	1.19	16632
2025-04-01	GMAB	18.67	0.54	4.45	16619
2025-04-02	GMAB	18.83	0.56	0.12	16802
2025-04-03	GMAB	19.25	0.56	1.28	16842
2025-04-04	GMAB	18.38	0.56	10.82	16891
2025-04-07	GMAB	18.2	0.57	1.65	16994
2025-04-08	GMAB	17.99	0.57	140.00	17023
2025-04-09	GMAB	18.84	0.58	2.40	17154
2025-04-10	GMAB	18	0.59	999.99	17227
2025-04-11	GMAB	18.82	0.59	0.00	17228
2025-04-14	GMAB	19.28	0.59	0.06	17236
2025-04-15	GMAB	19.5	0.59	0.99	17241
2025-04-16	GMAB	19.55	0.61	0.50	18587
2025-04-17	GMAB	20.02	0.61	1.50	18590
2025-04-18	GMAB	20.04	0.61	1.50	18590
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-20	GMAB	19.84	-14.6	-47.3	1.44
2025-03-21	GMAB	19.78	-14.6	-52.1	1.44
2025-03-24	GMAB	19.29	-14.6	-32.4	1.44
2025-03-25	GMAB	19.06	-14.6	-57.3	1.44
2025-03-26	GMAB	19.62	-14.6	38.7	1.44
2025-03-27	GMAB	20.15	-14.6	40.4	1.44
2025-03-28	GMAB	19.90	-14.6	-23.2	1.44
2025-03-31	GMAB	19.57	-14.6	-59.9	1.44
2025-04-01	GMAB	18.66	-21.4	-107.8	1.36
2025-04-02	GMAB	18.82	-21.4	56.6	1.38
2025-04-03	GMAB	19.24	-21.4	139.6	1.38
2025-04-04	GMAB	18.40	-21.4	-18.7	1.38
2025-04-07	GMAB	18.19	-21.4	8.8	1.38
2025-04-08	GMAB	17.98	-21.4	13.1	1.38
2025-04-09	GMAB	18.85	-21.4	-13.6	1.38
2025-04-10	GMAB	18.00	-21.4	54.2	1.38
2025-04-11	GMAB	18.82	-21.4	59.4	1.38
2025-04-14	GMAB	19.32	-21.4	-16.4	1.38
2025-04-15	GMAB	19.51	-21.4	-68.6	1.38
2025-04-16	GMAB	19.56	-21.4	-27.7	1.38
2025-04-17	GMAB	20.04	-21.4	17.8	1.38
2025-04-18	GMAB	20.04	-21.4	17.7	1.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-20	GMAB	0	0.84	0.36
2025-03-21	GMAB	0	0.84	0.36
2025-03-24	GMAB	0	0.80	0.36
2025-03-25	GMAB	0	0.80	0.36
2025-03-26	GMAB	0	0.80	0.48
2025-03-27	GMAB	0	0.80	0.48
2025-03-28	GMAB	0	0.80	0.48
2025-03-31	GMAB	0	0.80	0.48
2025-04-01	GMAB	0	0.80	0.48
2025-04-02	GMAB	0	0.80	0.48
2025-04-03	GMAB	0	0.80	0.48
2025-04-04	GMAB	0	0.80	0.48
2025-04-07	GMAB	0	0.92	0.48
2025-04-08	GMAB	0	0.92	0.48
2025-04-09	GMAB	0	0.92	0.48
2025-04-10	GMAB	0	0.92	0.34
2025-04-11	GMAB	0	0.92	0.34
2025-04-14	GMAB	0	0.96	0.34
2025-04-15	GMAB	0	0.96	0.34
2025-04-16	GMAB	0	0.96	0.35
2025-04-17	GMAB	0	0.96	0.35
2025-04-18	GMAB	0	0.96	0.35
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.57

Avg. EPS Est. Current Quarter

0.23

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

Institutional Transactions

0.96

Beta

1.01

Average Sales Estimate Current Quarter

5171

Average Sales Estimate Next Quarter

6293

Fair Value

28.59

Quality Score

100

Growth Score

100

Sentiment Score

Actual DrawDown %

59.2

Max Drawdown 5-Year %

-63.1

Target Price

30.93

P/E

11.44

Forward P/E

11.4

PEG

1.3

P/S

3.95

P/B

2.5

P/Free Cash Flow

11.14

EPS

1.75

Average EPS Est. Cur. Y

1.38

EPS Next Y. (Est.)

1.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

36.3

Relative Volume

0.7

Return on Equity vs Sector %

1.4

Return on Equity vs Industry %

14.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

17.7

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2682

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y